ECSP14013199A - Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio - Google Patents
Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorioInfo
- Publication number
- ECSP14013199A ECSP14013199A ECSP14013199A ECSP14013199A EC SP14013199 A ECSP14013199 A EC SP14013199A EC SP14013199 A ECSP14013199 A EC SP14013199A EC SP14013199 A ECSP14013199 A EC SP14013199A
- Authority
- EC
- Ecuador
- Prior art keywords
- sincicial
- prophylaxis
- respiratory
- compounds
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Un compuesto de la fórmula (I) (I)y sus sales farmacéuticamente aceptables, en la que de R1 a R10, A, Q, X e Y tienen los significados definidos en la descripción y en las reivindicaciones, pueden utilizarse como medicamentos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011078258 | 2011-08-11 | ||
| CN2012078439 | 2012-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14013199A true ECSP14013199A (es) | 2014-03-31 |
Family
ID=46651492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP14013199 ECSP14013199A (es) | 2011-08-11 | 2014-02-11 | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8871756B2 (es) |
| EP (1) | EP2742039B1 (es) |
| JP (1) | JP5746793B2 (es) |
| KR (1) | KR101570627B1 (es) |
| CN (1) | CN103717589B (es) |
| AU (1) | AU2012293644B2 (es) |
| BR (1) | BR112014003198B1 (es) |
| CA (1) | CA2842123C (es) |
| CL (1) | CL2014000311A1 (es) |
| CO (1) | CO6852080A2 (es) |
| CR (1) | CR20140026A (es) |
| EA (1) | EA023262B1 (es) |
| EC (1) | ECSP14013199A (es) |
| ES (1) | ES2552016T3 (es) |
| IL (1) | IL230458A (es) |
| MA (1) | MA35432B1 (es) |
| MX (1) | MX349881B (es) |
| MY (1) | MY184306A (es) |
| PE (1) | PE20142148A1 (es) |
| PH (1) | PH12014500164A1 (es) |
| WO (1) | WO2013020993A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR099134A1 (es) * | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| US9464055B2 (en) * | 2014-02-27 | 2016-10-11 | Janssen Pharmaceutica Nv | Quinoline derivatives useful as CB-1 inverse agonists |
| US9266835B2 (en) * | 2014-02-27 | 2016-02-23 | Janssen Pharmaceutica Nv | Quinoline derivatives useful as CB-1 inverse agonists |
| CN105726488B (zh) * | 2014-12-08 | 2020-10-20 | 上海爱科百发生物医药技术有限公司 | 含有呼吸道合胞病毒抑制剂的肠溶微丸及其制备方法 |
| CN104529802A (zh) * | 2014-12-13 | 2015-04-22 | 西安近代化学研究所 | 一种合成n,n′-双取代氟代丙二酰胺化合物的方法 |
| CN104860954B (zh) * | 2015-04-20 | 2018-05-04 | 南京天印健华医药科技有限公司 | 一种苯酯螺吡咯烷类化合物及其制备方法 |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3322704B1 (en) | 2015-07-16 | 2019-11-27 | H. Hoffnabb-La Roche Ag | Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脊髄性筋萎縮症を処置するための組成物 |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| BR112021004266A2 (pt) | 2018-09-06 | 2021-08-03 | Cidara Therapeutics, Inc. | conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático |
| CN113412260B (zh) * | 2019-01-29 | 2022-08-02 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| WO2021050612A1 (en) * | 2019-09-09 | 2021-03-18 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
| GB201915273D0 (en) * | 2019-10-22 | 2019-12-04 | Reviral Ltd | Pharmaceutical compounds |
| WO2021083290A1 (en) * | 2019-10-31 | 2021-05-06 | Shanghai Ark Biopharmaceutical Co. Ltd. | Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same |
| GB201915932D0 (en) * | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| WO2022010948A1 (en) * | 2020-07-06 | 2022-01-13 | Crescenta Biosciences | Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| CN113234085A (zh) * | 2021-04-26 | 2021-08-10 | 无锡合全药业有限公司 | 一种2-氧杂-6-氮杂螺[3.4]辛烷-8-基氨基甲酸叔丁酯的合成方法 |
| CN118239945A (zh) * | 2022-12-22 | 2024-06-25 | 甫康(上海)健康科技有限责任公司 | 一种苯并硫氮杂卓类化合物及其制备方法与用途 |
| WO2025011580A1 (zh) | 2023-07-10 | 2025-01-16 | 石药集团中奇制药技术(石家庄)有限公司 | 用于治疗和预防呼吸道合胞病毒感染疾病的化合物 |
| WO2025190151A1 (zh) * | 2024-03-13 | 2025-09-18 | 甫康(上海)健康科技有限责任公司 | 一种苯并硒氮杂*类化合物及其制备方法与用途 |
| CN120794971A (zh) * | 2024-04-10 | 2025-10-17 | 广州医科大学 | 二氨基嘧啶化合物及其用途 |
| WO2025252264A1 (zh) * | 2024-06-07 | 2025-12-11 | 武汉武药科技有限公司 | 用于治疗或预防呼吸道合胞病毒疾病的化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US5874438A (en) * | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| CA2548407A1 (en) * | 2003-12-12 | 2005-07-07 | Qtl Biosystems Llc | Metal ion mediated fluorescence superquenching assays, kits and reagents |
| NZ551468A (en) * | 2003-12-24 | 2010-05-28 | Biota Scient Management | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
-
2012
- 2012-07-30 US US13/561,366 patent/US8871756B2/en not_active Ceased
- 2012-08-08 CA CA2842123A patent/CA2842123C/en active Active
- 2012-08-08 BR BR112014003198-3A patent/BR112014003198B1/pt active IP Right Grant
- 2012-08-08 MY MYPI2014700267A patent/MY184306A/en unknown
- 2012-08-08 ES ES12746320.6T patent/ES2552016T3/es active Active
- 2012-08-08 EP EP12746320.6A patent/EP2742039B1/en active Active
- 2012-08-08 WO PCT/EP2012/065499 patent/WO2013020993A1/en not_active Ceased
- 2012-08-08 PH PH1/2014/500164A patent/PH12014500164A1/en unknown
- 2012-08-08 JP JP2014524370A patent/JP5746793B2/ja active Active
- 2012-08-08 AU AU2012293644A patent/AU2012293644B2/en active Active
- 2012-08-08 PE PE2014000187A patent/PE20142148A1/es active IP Right Grant
- 2012-08-08 EA EA201490419A patent/EA023262B1/ru not_active IP Right Cessation
- 2012-08-08 MX MX2014001481A patent/MX349881B/es active IP Right Grant
- 2012-08-08 CN CN201280039193.0A patent/CN103717589B/zh active Active
- 2012-08-08 KR KR1020147006355A patent/KR101570627B1/ko active Active
-
2014
- 2014-01-14 IL IL230458A patent/IL230458A/en active IP Right Grant
- 2014-01-17 CO CO14008865A patent/CO6852080A2/es active IP Right Grant
- 2014-01-20 CR CR20140026A patent/CR20140026A/es unknown
- 2014-02-07 CL CL2014000311A patent/CL2014000311A1/es unknown
- 2014-02-11 EC ECSP14013199 patent/ECSP14013199A/es unknown
- 2014-03-11 MA MA36815A patent/MA35432B1/fr unknown
-
2020
- 2020-10-21 US US17/075,948 patent/USRE49481E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14013199A (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| ECSP13013074A (es) | Nuevos derivados de piridina | |
| GT201400131A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| ECSP15000435A (es) | Inhibidores macrocíclicos de virus flaviviridae | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| ECSP13012417A (es) | Derivados de ácido napht-2-ilacético para tratar sida | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
| MX2014005342A (es) | Inhibidores del virus de la hepatitis c. | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| EA201490919A1 (ru) | Производные бетулина | |
| CR20150204A (es) | Nuevos derivados de piridina | |
| DOP2014000265A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| CO6741154A2 (es) | Compuestos de triazolopiridina | |
| UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CO7350640A2 (es) | Compuestos diméricos | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| CR20150511A (es) | Nuevos derivados de purina |